Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PMDA-WEST to Be Launched in Osaka in October to Undertake Consultation Services, GMP Inspections
May 13, 2013
- Generic Drug Makers Make Only about 20% of Bulk Drug Substances Available from Multiple Sources: Dr Muto of JSGM
May 7, 2013
- MHLW Approves 2 Cell Culture-Based New Influenza Vaccines
May 7, 2013
- PMDA Announces "International Vision and Roadmap"
May 7, 2013
- MEXT to Award Up to 100 Million Yen Each to 15 National University Hospitals that Lead in Generic Drug Use
May 2, 2013
- Application of New Price Reduction Rule for Long-listed Drugs Should Distinguish between Products Which Received or Did Not Receive Premium: Mr Kamoya of FPMAJ
May 1, 2013
- First Committee Recommends Approval for New Gout, Hyperuricemia Treatment, Antihypertensive Tape Formulation
May 1, 2013
- PMRJ Introduces “RS Expert Certification System”
April 30, 2013
- PAFSC’s Second Committee Recommends Approval for Chugai’s Breast Cancer Drug Perjeta, Others
April 26, 2013
- Japan-Version NIH: Cabinet HQ to Lay Out Comprehensive Strategy, Integrate R&D Budgets
April 25, 2013
- Bill to Amend PAL Will Be Submitted to Diet in May, as Instructed by PM Abe: Mr Akagawa of PFSB
April 25, 2013
- MHLW Picks Additional Clinical Research Core Hospitals
April 23, 2013
- MHLW May Refuse Applications for Generic Drug Listing from Companies that Fail to Maintain Stable Supplies
April 23, 2013
- Experts on Council for Science and Technology Policy Back Measures to Promote Development of Innovative New Drugs Aiming at Healthy, Long-lived Society
April 19, 2013
- Reorganization of Council for Science and Technology Policy Proposed by Industrial Competitiveness Council to Create Stronger Centralized Authority
April 19, 2013
- First Committee to Discuss Approval of New Gout Treatment Topiroxostat
April 18, 2013
- Committee Finds No Problem with Quality of 8 Generic Versions of Pfizer Japan’s Unasyn-S Kit
April 18, 2013
- “Japanese Version of CTEP” Proposed at 1st Meeting of Expert Council on Future Cancer Research
April 16, 2013
- Growing Concern Over Return to Brand Names for Generics with Advent of Generic Versions of Combination Drugs
April 16, 2013
- PAFSC’s Second Committee to Review Chugai’s Breast Cancer Drug Pertuzumab on April 25
April 15, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…